Case report | Open | Open Peer Review | Published:
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature
Journal of Medical Case Reportsvolume 12, Article number: 64 (2018)
Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both. Richter’s transformation to diffuse large B-cell lymphoma is frequently observed in chronic lymphocytic leukemia. Purine analog therapy and the presence of trisomy 12, and CCND1 gene rearrangement have been linked to increased risk of Richter’s transformation. The coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma in the same patient is extremely rare, with only nine reported cases. Here, we describe the first reported case of concurrent chronic myeloid leukemia and diffuse large B-cell lymphoma in a background of chronic lymphocytic leukemia.
A 60-year-old Saudi man known to have diabetes, hypertension, and chronic active hepatitis B was diagnosed as having Rai stage II chronic lymphocytic leukemia, with trisomy 12 and rearrangement of the CCND1 gene in December 2012. He required no therapy until January 2016 when he developed significant anemia, thrombocytopenia, and constitutional symptoms. He received six cycles of fludarabine, cyclophosphamide, and rituximab, after which he achieved complete remission.
One month later, he presented with progressive leukocytosis (mostly neutrophilia) and splenomegaly. Fluorescence in situ hybridization from bone marrow aspirate was positive for translocation (9;22) and reverse transcription polymerase chain reaction detected BCR-ABL fusion gene consistent with chronic myeloid leukemia. He had no morphologic or immunophenotypic evidence of chronic lymphocytic leukemia at the time. Imatinib, a first-line tyrosine kinase inhibitor, was started. Eight months later, a screening imaging revealed new liver lesions, which were confirmed to be diffuse large B-cell lymphoma.
In chronic lymphocytic leukemia, progressive leukocytosis and splenomegaly caused by emerging chronic myeloid leukemia can be easily overlooked. It is unlikely that chronic myeloid leukemia arose as a result of clonal evolution secondary to fludarabine treatment given the very short interval after receiving fludarabine. It is also unlikely that imatinib contributed to the development of diffuse large B-cell lymphoma; rather, diffuse large B-cell lymphoma arose as a result of Richter’s transformation. Fludarabine, trisomy 12, and CCND1 gene rearrangement might have increased the risk of Richter’s transformation in this patient.
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world. It is characterized by progressive accumulation of mature B or T lymphocytes in the peripheral blood, bone marrow, liver, and lymphoid organs [1, 2].
CML is a chronic myeloproliferative neoplasm with an annual incidence of 1–2 cases per 100,000 people per year. It originates from abnormal hematopoietic stem cells induced by the BCR-ABL oncogene, resulting in the involvement of multiple hematopoietic lineages, but predominantly myeloid cells .
Despite the frequent occurrence of CLL and CML in adults, it is rare for the two to coexist [4,5,6,7,8,9]. The association between lymphoproliferative disorders (LPD) and myeloid malignancies, such as acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative disorders, is not well understood; however, it is possible that two malignant clones might arise from the same cancerous stem cell .
In CLL, Richter’s transformation (RT) to Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), is frequently observed and usually has a poor outcome [11, 12].
To the best of our knowledge, CLL, CML, and DLBCL have never been reported to coexist. Here we describe the first case of the coexistence of CML and DLBCL in a patient with antecedent CLL.
A 60-year-old Saudi man with a history of diabetes, hypertension, and chronic active hepatitis B, an entrepreneur, married with seven children, who denied tobacco smoking, alcohol consumption, and illicit drug use, was initially seen at our facility and was diagnosed as having Rai stage II CLL in December 2012. His physical examination at presentation revealed a moderately built man. His respiratory and cardiovascular examination was normal. His liver was normal in size but his spleen was palpable (8 cm below the costal margin). He had generalized lymphadenopathy involving his neck, axillae, and bilateral inguinal regions; however, the lymph nodes were 1–3 cm in size. A neurological examination revealed no focal neurological deficit. His serum creatinine at presentation was 72 umol/L, and his blood urea nitrogen (BUN) was 4.3 mmol/L. The results of his liver function test were: aspartate aminotransferase (AST) 22 unit/L, alanine transaminase (ALT) 27 unit/L, total bilirubin 12.1 umol/L, albumin 3.5 g/dL, and alkaline phosphatase of 68 unit/L. His blood count at presentation showed a white blood cell (WBC) count of 28.9 × 109/L, hemoglobin (Hb) level of 13.4 g/dl, a platelet count of 106 × 109/L, and an absolute lymphocyte count (ALC) of 25.1 × 109/L (Fig. 1). Peripheral blood flow cytometry revealed 43% of total acquired events co-expressing CD5, CD19, CD23, CD79b, and cytoplasmic CD79a, but lacking surface immunoglobulin light chains, CD10, and CD38. Bone marrow aspirate and biopsy (BMAB) showed hypercellular bone marrow with diffuse intestinal and focal paratrabecular lymphocytic infiltrate. The lymphocytes were mature, small, and positive for CD20, CD79a, PAX-5, CD5, CD23, and BCL2, but negative for cyclin D1 and CD10 (Fig. 2). Conventional cytogenetic tests and fluorescence in situ hybridization (FISH) revealed that 27% of analyzed cells displayed rearrangement of the CCND1 gene in chromosome 11 and 15% of cells had trisomy 12, but t(11;14) (q13;q32) was not detected (Fig. 3).
A computed tomography (CT) scan of his neck, chest, abdomen, and pelvis showed hepatomegaly with focal hypodense liver lesions and massive splenomegaly (20.9 × 7.3 cm) (Fig. 4a, b). A liver biopsy showed infiltration with small lymphocytic lymphoma (SLL; Fig. 5). He remained under surveillance until January 2016, when he developed anemia, thrombocytopenia, and significant constitutional symptoms. He was started on chemoimmunotherapy with fludarabine 25 mg/m2 on days 1–3, cyclophosphamide 250 mg/m2 on days 1–3, and rituximab 375 mg/m2 on day 1 (FCR) for a total of six cycles, until 27 July 2016. His blood counts normalized (Fig. 1). And an end-of-therapy CT scan showed resolution of the liver lesions, and significantly reduced lymphadenopathy and splenomegaly.
One month after completing FCR therapy, his leukocytosis (mostly neutrophilia) returned, with myeloid left shift. His spleen was palpable 10 cm below the costal margin. His WBC count reached 93 × 109/L, Hb 10.9 g/dl, platelet count 61 × 109/l, absolute neutrophil count 42 × 109/L, and eosinophil count 3 × 109/L. Peripheral blood blasts and basophils were 1% each (Fig. 1). BMAB was suboptimal. Conventional cytogenetic analysis using bone marrow showed Philadelphia chromosomes in all examined cells with no other cytogenetic aberrations. FISH analysis revealed presence of the BCR-ABL fusion gene in 100% of cells examined, and quantitative reverse transcription polymerase chain reaction (RT-PCR) of peripheral blood showed a ratio of BCR-ABL/ABL of 21% (Fig. 3).
Since the morphologic findings of both the blood smear and the cytogenetics were compatible with chronic phase CML, he was started on first-generation tyrosine kinase inhibitor (TKI) imatinib at a dose of 400 mg daily. As a result, his complete blood count normalized and his spleen shrank. Although he achieved an appropriate hematologic response within 3 months of imatinib treatment, on 21 March 2017 he demonstrated a suboptimal molecular response with a BCR-ABL/ABL ratio of 17%. Subsequently, he was switched to 300 mg orally administered nilotinib (a second-generation TKI) twice daily. After 3 months of nilotinib treatment, the BCR-ABL/ABL ratio dropped to 0.093%.
To screen for hepatocellular carcinoma, an abdominal CT scan was done in March 2017 and it revealed multiple hypoechoic liver lesions (Fig. 4c). Magnetic resonance imaging of his liver confirmed the presence of at least nine hepatic lesions (Fig. 4d, e). Positron emission tomography (PET) showed multiple metabolically active liver lesions (Fig. 4f). A liver biopsy performed in May 2017 confirmed RT to high-grade B cell lymphoma. After negative tests for c-MYC, the final pathological diagnosis was confirmed as DLBCL (Fig. 6). Staging BMAB was morphologically negative for CLL, CML, and DLBCL. FISH analysis on BMAB was negative for CCND1 gene rearrangement, trisomy 12, and BCR-ABL oncogene.
While awaiting c-MYC in situ hybridization he received two cycles of chemoimmunotherapy by infusion consisting of rituximab 375 mg/m2 on day 1, etoposide 50 mg/m2 on days 1–4, prednisone 60 mg/m2 on days 1–5, doxorubicin 10 mg/m2 on days 1-4, Oncovin (vincristine) 0.5 mg/m2 on days 1–4, and cyclophosphamide (R-EPOCH). He was then switched to rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, doxorubicin 50 mg/m2 on day 1, oncovin (vincristine) 50 mg/m2 on day 1, vincristine 1.4 mg/m2 on day 1, and prednisone 100 mg days 1–5 (R-CHOP); he completed four cycles. Radiological assessment with PET/CT at the end of chemotherapy was consistent with complete metabolic response.
A donor had been identified in preparation for allogeneic hematopoietic stem cell transplantation, in case our patient’s CML proved resistant to second-line TKI treatment. He was last seen in January 2018, 8 months after his diagnosis with DLBCL with no evidence of lymphoma and his BCR-ABL/ABL ratio dropped to 0.01%.
The patient in the present case report remained under careful observation for 3 years after being diagnosed as having CLL. Soon after completing fludarabine-based chemotherapy, he was diagnosed with CML. It is possible that this CML already existed before and was only detected after his CLL was brought under control. Alternatively, it is possible that CML arose as a result of clonal evolution secondary to fludarabine treatment. However, this theory is less likely given the very short interval between receiving purine analog (PNA) and CML emergence.
Despite increasing rates of complete remission in CLL associated with fludarabine-based regimens, RT still occurs, warranting continued surveillance regardless of disease status. RT to NHL, HL, and multiple myeloma develops in approximately 3%, 0.5%, and 0.1% of patients, respectively. Risk factors for RT include advanced Rai stage at diagnosis, TP53 disruption, c-MYC abnormalities, non-deletion 13q cytogenetics, CD38 gene polymorphism, and unmutated immunoglobulin heavy chain variable region gene status [10,11,12,13].
Patients treated for CLL with PNA and alkylating agents tend to have an up to three-fold increased risk of RT compared to those who have not received PNA [14, 15]. The median time from first treatment of CLL to the development of second LPD is 2.4 years . Although our patient was in complete remission from CLL/SLL when he was diagnosed as having DLBCL, we believe that RT was the cause rather than de novo DLBCL. This is based on biopsy evidence of CLL infiltration of his liver at the time of his initial diagnosis in 2012.
The immune-compromised state of CLL patients means that they have a frequency of secondary tumors. These are not limited to LPD, but also include solid tumors such as cancers of the lung, colorectal region, bladder, breast, central nervous system, stomach, ovaries, head, neck, and testicles, as well as melanoma, sarcoma, and myeloid leukemias .
Cytogenetic analysis of our patient revealed trisomy 12, which is a cytogenetic abnormality frequently seen in CLL and associated with a higher frequency of RT to DLBCL attributed to activation of the NOTCH1 pathway . In our patient, rearrangement of the CCND1 gene was also observed, which might have increased his risk of RT .
The development of TKIs, a major breakthrough in the therapy of CML, has dramatically improved the survival of patients with CML. However, the use of TKIs may be associated with the development of secondary malignancies. Around 7% of patients with TKI-treated CML develop non-hematologic secondary malignancies. On the other hand, this increased risk may be linked to CML itself rather than to TKI treatment . The coexistence of CML with DLBCL in the same patient is even rarer, with only nine cases reported to date [21,22,23,24,25]. In the case reported here, it is unlikely that TKI therapy contributed to the development of DLBCL; rather, DLBCL arose as a result of RT of the antecedent CLL.
In CLL, progressive leukocytosis and splenomegaly caused by emerging CML might be overlooked unless care is taken to examine the white cell differential, and appropriate further tests are carried out. It is unlikely that CML arose as a result of clonal evolution secondary to fludarabine treatment given the very short interval between receiving fludarabine and CML emergence. It is also unlikely that CML therapy contributed to the development of DLBCL; rather, DLBCL arose as a result of RT of CLL. Fludarabine therapy, trisomy 12, and CCND1 gene rearrangement might have increased the risk of RT in this patient.
To the best of our knowledge, this is the first reported case of concurrent CML and DLBCL against a background of CLL. This case represents a tremendous medical challenge, especially with the failure of CML to respond to first-line TKI and in a background of chronic liver disease.
Absolute lymphocyte count
Bone marrow aspirate and biopsy
Blood urea nitrogen
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Diffuse large B-cell lymphoma
Fludarabine, cyclophosphamide and rituximab
Fluorescence in situ hybridization
Positron emission tomography
Rituximab, cyclophosphamide, doxurubicin, oncovin (vincristine) and prednisone
Rituximab, etoposide, prednisone, doxorubicin, oncovin and cyclophosphamide
Reverse transcription polymerase chain reaction
Small lymphocytic lymphoma
Tyrosine kinase inhibitor
White blood cell
National Institutes of Health, National Cancer Institute. Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/clyl.html. Accessed 2 Nov 2017.
Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischillies EA. Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval. Leuk Lymphoma. 2017; https://doi.org/10.1080/10428194
Garcia-Manero G, Faderl S, O’Brien S, Cortes J, Talpez M, Kantarjan HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437–57.
Chang H, Sutherland R, Nayar R, Li D, Kamel-Reid S, Mile MA, et al. Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence activated cell sorting. Cancer Genet Cytogenet. 2004;152:146–8.
Mansat-De Mas V, Rigal-Huquet F, Cassar G, Kuhlein E, Laurent G, Dastugue N. Chronic myeloid leukemia associated with B-cell chronic lymphocytic leukemia: evidence of two separate clones as shown by combined cell-sorting and fluorescence in situ hybridisation. Leuk Lymphoma. 2003;44:867–9.
CrisanAM BSN, Jardan C, Vasilache ED, Dobera C, Gheorghe A, et al. The occurrence of chronic lymphocytic leukemia after chronic phase of chronic myeloid leukemia: case report and literature review. Rom J Morph Embrol. 2015;56:1145–51.
Laurenti L, Tarnani M, Nichele I, Clolli S, Cortelezzi A, Forconi F, et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicenteric GIMEMA experience. Am J Hematol. 2011;86:1007–12.
Fattizzo B, Radice T, Cattaneo D, Pomati M, Barcellini W, Iurol A. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia. Clin Lab. 2014;60:1929–32.
Esteve J, Cervantes F, Rives S, Rozman M, Zarco MA, Montserrat E. Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis. Haematologica. 1997;82:596–9.
Tsimberidou AM, Keating MJ. Richter’s transformation in CLL. Semin Oncol. 2006;33:250–6.
Jain P, O’Brien S. Richter’s transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26:1146–52.
Parikh SA, Shanafelt TD. Risk factors for Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014;9:294–9.
Maddocks-Christianson K, Slager SL, Zent CS, Reinaida M, Call TG, Habermann TM, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukemia. Br J Haematol. 2007;139:398–404.
Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005;103:216–28.
Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse Large B-Cell Lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162:774–82.
Ayers EC, Mato AR. Richter’s Transformation in the Era of Kinase Inhibitor Therapy: A Review. Clin Lymphoma Myeloma Leuk. 2017;17(1):1–6.
Cheson BD, Vena DA, Barrett J, Freidin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphocytic leukaemias. J Clin Oncol. 1999;17:2454–60.
Brynes RK, McCourty A, Sun NC, Koo CH. Trisomy 12 in Richter’s transformation of chronic lymphocytic leukemia. Am J Clin Pathol. 1995;104:199–203.
Cobo F, Martinez A, Pinyol M, Hernandez L. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia. 2002;16:1028–34.
Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169:683–8.
Breccia M, Martelli M, Cannella L, Russo E, Finolezzi E, Stefanizzi C, et al. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukemia and relapsed non-Hodgkin lymphoma. Leuk Res. 2008;32:353–5.
Acar H, Ecirli S, Gundogan F, Bullay O, Acar A. Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis. Cancer Genet Cytogenet. 1999;108:171–4.
Zamecnikova A, Vranovsky A, Hlvcak P. Coexistance of Philadelphia-positive chronic granulocytic leukemia and diffuse large B-cell lymphoma at initial diagnosis. Leuk Lymphoma. 2002;43:429–31.
Louis R, Gupta SK, Jain S, Mehta A, Agarwal M. Therapy related Chronic Myeloid Leukemia (trCML) on non-Therapy Related Second Malignancy Chronic Myeloid Leukemia (smCML) following Diffuse Large B-Cell Lymphoma (DLBCL): A Case Report and review of Literature. Am J Cancer Case Rep. 2016;4:1–9.
Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, et al. Ph-negative non-Hodgkin’s lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia. 2000;14:169–82.
We acknowledge Mr Hussam Shehata.
Availability of data and materials
Not applicable; no datasets were generated for this case report.
Ethics approval and consent to participate
The need for approval was waived by King Abdullah International Research Center.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
- Chronic lymphocytic leukemia
- Chronic myeloid leukemia
- Richter’s transformation
- Diffuse large B-cell lymphoma
- Purine analogs
- Tyrosine kinase inhibitors